Agilent TechnologiesFRA:AG8 -0.25%91 FCF Margin % is 10.95% as of Apr. 2026, which is 34% below its 10-year median of 16.67. GuruFocus rates FRA:AG8 with a GF Score™ of 91/100 and a GF Value™ of €127.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 83.82% on this metric.
The historical rank and industry rank for Agilent Technologies's FCF Margin % or its related term are showing as below:
FRA:AG8'
s FCF Margin % Range Over the Past 10 Years
Min: 14.91 Med: 16.67 Max: 21.57
Current: 15.05
During the past 13 years, the highest FCF Margin % of Agilent Technologies was 21.57%. The lowest was 14.91%. And the median was 16.67%.
FRA:AG8's FCF Margin % is ranked better than 83.82% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs FRA:AG8: 15.05
Agilent Technologies FCF Margin % Related Terms
Agilent Technologies FCF Margin % Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AG8 vs WAT, IDXX, NTRA: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (FRA:AG8) has a FCF Margin % of 10.95% as of Apr. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Agilent Technologies and its competitors. This is 34% below median its historical median of 16.67. Over the past decade, Agilent Technologies' FCF Margin % has ranged from 14.91 to 21.57. According to the industry distribution chart, Agilent Technologies ranks #33 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 16.2%.
Is Agilent Technologies' FCF Margin % too high?
Agilent Technologies' current FCF Margin % of 10.95% is 34% below median its 10-year median of 16.67. Over the past 10 years, this metric has ranged from a low of 14.91 to a high of 21.57. Based on the distribution chart, Agilent Technologies ranks #33 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Agilent Technologies has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' FCF Margin % compare to WAT and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #33 out of 204 companies for FCF Margin %. This places Agilent Technologies in the top 16% of its industry — outperforming the majority of peers. Historically, Agilent Technologies' own FCF Margin % has ranged from 14.91 to 21.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current FCF Margin % is 10.95%, which is 34% below median its own 10-year median of 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Fairly Valued. The stock's GF Value™ is €127.48, compared to a current price of €119.35 — trading 6.4% below its estimated fair value. The current FCF Margin % is 10.95%, which is 34% below median its 10-year median of 16.67. Agilent Technologies' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current FCF Margin % is 10.95% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €119.35 is trading 6.4% below its estimated GF Value™ of €127.48.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for FRA:AG8:
FCF Margin %: 10.95% (34% below median its 10-year median of 16.67)
GF Value™: €127.48 vs. price of €119.35 (6.4% below fair value)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
91GF Score
Get the complete analysis for FRA:AG8
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
